Toyama Tetsuya | Department Of Gastroenterology And Hepatology Osaka University

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts
Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance
Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B
Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis
Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma
Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection
Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine
Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C
Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection
Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?
The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan
Restoration of gut motility in Kit-deficient mice by bone marrow transplantation
Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C : a Japanese multi-center study
Clinical characteristics and prevalence of GB virus C, SEN virus, and HFE gene mutation in Japanese patients with nonalcoholic steatohepatitis
Activated Kupffer cells play an important role in intra-hepatic Th1-associated necro-inflammation in Concanavalin A-induced hepatic injury in mice
Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan
STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo
Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet
Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C
Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan
Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan
Differential alteration of CD56^ and CD56^ natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection
Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels : a matched case-control study
Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection
Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin

もっと見る

スポンサーリンク